Evidence map›Paper›PMID 24691433›Full record

ArticleScientific reports2014

Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms.

Daniel J Kota, Bryan DiCarlo, Robert A Hetz, Philippa Smith, Charles S Cox, Scott D Olson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel J KotaDepartment of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin St., MSB 5.233, Houston, TX, USA 77030.
Bryan DiCarloDepartment of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin St., MSB 5.233, Houston, TX, USA 77030.
Robert A HetzDepartment of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin St., MSB 5.233, Houston, TX, USA 77030.
Philippa SmithDepartment of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin St., MSB 5.233, Houston, TX, USA 77030.
Charles S CoxDepartment of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin St., MSB 5.233, Houston, TX, USA 77030.
Scott D OlsonDepartment of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin St., MSB 5.233, Houston, TX, USA 77030.
The University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in the field of Multipotent Mesenchymal Stromal cell (MSC) biology have demonstrated that MSCs can improve disease outcome when 'activated' to exert immunomodulatory effects. However, the precise mechanisms modulating MSC-immune cells interactions remain largely elusive. In here, we activated MSC based on a recent polarization paradigm, in which MSCs can be polarized towards a pro- or anti-inflammatory phenotype depending on the Toll-like receptor stimulated, to dissect the mechanisms through which MSCs physically interact with and modulate leukocytes in this context. Our data show that MSCs activated through the Toll-like receptor (TLR) 4 pathway increased VCAM-1 and ICAM-1 dependent binding of leukocytes. On the other hand, TLR3 stimulation strongly increases leukocytes affinity to MSC comparatively, through the formation of cable-like hyaluronic acid structures. In addition, TLR4 activation elicited secretion of pro-inflammatory mediators by MSCs, whereas TLR3-activated MSCs displayed a milder pro-inflammatory phenotype, similar to inactivated MSCs. However, the differently activated MSCs maintained their ability to suppress leukocyte activation at similar levels in our in vitro model, and this immunomodulatory property was shown here to be partially mediated by prostaglandin. These results reinforce the concept that alternate activation profiles control MSC responses and may impact the therapeutic use of MSCs.

Indexed as

Cell CommunicationCell DifferentiationCells, CulturedHumansInflammationIntercellular Adhesion Molecule-1Leukocytes, MononuclearMesenchymal Stem CellsToll-Like Receptor 3Toll-Like Receptor 4Vascular Cell Adhesion Molecule-1Intercellular Adhesion Molecule-1TLR4 protein, humanToll-Like Receptor 3Toll-Like Receptor 4Vascular Cell Adhesion Molecule-1

Identifiers

PMID24691433
PMCPMC3972508
OpenAlexW2036675540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.